A ruthenium compound represented by a general formula described in the specification, a raw material which is for forming a thin film and which contains the ruthenium compound, and a method of producing a thin film using the raw material for forming a thin film are provided.

A compound of the formula ML.sub.AL.sub.B where ligand L.sub.A is of Formula I, and ligand L.sub.B is of Formula II below. ##STR00001## M is selected from Os(II) or Ru(II), and the compound ML.sub.AL.sub.B has a formal neutral charge; and rings A, B, C, D, E, and F are independently a 5-membered or 6-membered aromatic ring, and R.sup.A, R.sup.B, R.sup.C, R.sup.D, R.sup.E,and R.sup.F each independently represent mono to the maximum allowable substitution, or no substitution. L.sup.1, L.sup.2, L.sup.3, and L.sup.4 independently represent a single bond or an organic linking group; W.sup.1, W.sup.2, W.sup.3, and W.sup.4 are independently selected from carbon or nitrogen; Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are independently selected from carbon or nitrogen; and Z.sup.1, Z.sup.2, and Z.sup.3 are independently selected from carbon or nitrogen, and at least one of Z.sup.1, Z.sup.2, and Z.sup.3 is nitrogen. An organic electroluminescent device that includes an anode, a cathode, and an organic layer comprising a compound of the formula ML.sub.AL.sub.B where ligand L.sub.A is of Formula I, and ligand L.sub.B is of Formula II above. A consumer product comprising an organic light-emitting device (OLED) above.

Embodiments in accordance with the present invention encompass compositions encompassing a latent organo-ruthenium compound and a pyridine compound along with one or more monomers which undergo ring open metathesis polymerization (ROMP) when said composition is exposed to suitable actinic radiation to form a substantially transparent film. Surprisingly, the compositions are very stable at ambient conditions to temperatures up to 80° C. for several days and undergo mass polymerization when subject only to actinic radiation. Accordingly, compositions of this invention are useful in various opto-electronic applications, including as 3D printing materials, coatings, encapsulants, fillers, leveling agents, among others.

Methods for preparing conjugated dienes are described. An α,β-unsaturated E olefin intermediate may be prepared via cross-metathesis using a catalyst comprising a transition metal (e.g., ruthenium), a first carbene ligand (e.g., a substituted indenylidene) and an N-heterocyclic carbene ligand (e.g., an imidazolidinylidene). The catalyst further includes a phenylphosphine ligand, a tri(isopropoxy)phosphine ligand, a dimethylsulfoxide ligand, an acetonitrile ligand, or a pyridine ligand. Following the cross metathesis-step, the α,β-unsaturated aldehyde intermediate may be converted to the conjugated diene product via reaction with a phosphonium ylide. Products obtained via the methods of the disclosure include (7E,9Z)-dodeca-7,9-dien-1-yl acetate, a pheromone produced by Lobesia botrana (European grapevine moth), and other insect pheromones.

This invention relates generally to olefin metathesis catalysts, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, and the use of such compounds in the metathesis of olefins and in the synthesis of related olefin metathesis catalysts. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and in industrial applications such as oil and gas, fine chemicals and pharmaceuticals.

The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.

Through the use of a rhodamine appended chelate, a versatile strategy has been demonstrated to generate mitochondria-targeting photosensitizers via the incorporation of variety of luminescent transition metal systems. The generation of triplet excited state of rhodamine moiety endows the complexes with mitochondria-targeting photosensitizing ability to form singlet oxygen (.sup.1O.sub.2) for use as photodynamic therapy (PDT) agent. The combination of rhodamine organic dye and luminescent transition metal centers in such hybrid systems exhibits the synergistic merits, including low dark cytotoxicity, selective tumor cell uptake, high molar absorptivity for low-energy excitation in the visible region, and high photostability.

This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.

An organic light-emitting device includes: a first electrode; a second electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1. The organic light-emitting device including the organometallic compound may have a low driving voltage, a high luminance, a high efficiency, and a long lifespan: ##STR00001##

Novel ruthenium complexes of general formula 4

##STR00001##

in which the substituents are defined herein. The present disclosure relates also to methods for preparing such compounds and use thereof as catalysts and/or (pre)catalysts in olefin cross metathesis.